Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: A proposal for a thickness-based definition of sBCC

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 549-554

  McKay, K M ^a   Sambrano, B L ^b   Fox, P S ^b   Bassett, R L ^b   Chon, S ^b   Prieto, V G ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUPERFICIAL BASAL CELL CARCINOMA; THICKNESS;

ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84883416220     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12402     Document Type: Article

References (40)

1. Housman TS, Feldman SR, Williford PM, et al,. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003; 48: 425-9.
2. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society, 2012.
3. Katz MH,. Nonmelanoma skin cancer. Md Med J 1997; 46: 239-42.
4. Chen JG, Fleischer AB Jr, Smith ED, et al,. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 2001; 27: 1035-8.
5. Flohil SC, de Vries E, Neumann HA, et al,. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91: 24-30.
6. Bath-Hextall F, Leonardi-Bee J, Smith C, et al,. Trends in incidence of skin basal cell carcinoma. Additional evidence from a U.K. primary care database study. Int J Cancer 2007; 121: 2105-8.
7. Christenson LJ, Borrowman TA, Vachon CM, et al,. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294: 681-90.
8. Neville JA, Welch E, Leffell DJ,. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007; 4: 462-9.
9. Schulze HJ, Cribier B, Requena L, et al,. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-47.
10. Raasch B,. Management of superficial basal cell carcinoma: focus on imiquimod. Clin Cosmet Investig Dermatol 2009; 2: 65-75.
11. Gaspari AA, Tyring SK, Rosen T,. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 2009; 8: 467-74.
12. Love WE, Bernhard JD, Bordeaux JS,. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-8.
13. Oldfield V, Keating GM, Perry CM,. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol 2005; 6: 195-200; discussion 201-2.
14. Quirk C, Gebauer K, Owens M, Stampone P,. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006; 47: 258-65.
15. Aguilar M, de Troya M, Martin L, et al,. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities. J Eur Acad Dermatol Venereol 2010; 24: 1431-6.
16. Geisse JK, Rich P, Pandya A, et al,. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
17. International Agency for Research on Cancer (IARC). World Health Organization classification of tumours, pathology and genetics. Skin Tumours. (, LeBoit PE, Burg G, Weedon D, Sarasin A, eds). Lyon: IARC Press, 2006.
18. Sexton M, Jones DB, Maloney ME,. Histological pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990; 23: 1118-26.
19. Sloane JP,. The value of typing basal cell carcinomas in predicting recurrence after surgical excision. Br J Dermatol 1977; 96: 127-32.
20. Rippey JJ,. Why classify basal cell carcinomas? Histopathology 1998; 32: 393-8.
21. Lang PG Jr, Maize JC,. Histologic evolution of recurrent basal cell carcinoma and treatment implications. J Am Acad Dermatol 1986; 14: 186-96.
22. Emmett AJ,. Surgical analysis and biological behaviour of 2277 basal cell carcinomas. Aust N Z J Surg 1990; 60: 855-63.
23. Thackray AC,. Histological classification of rodent ulcers and its bearing on their prognosis. Br J Cancer 1951; 5: 213-24.
24. Madsen A. De, l'epithelioma baso-cellulaire superficiel. Acta Derm Venereol 1941; 22 (Suppl. 7): 1-161.
25. Madsen A,. The histogenesis of superficial basal-cell epitheliomas; unicentric or multicentric origin. AMA Arch Derm 1955; 72: 29-30.
26. Lang PG Jr, McKelvey AC, Nicholson JH,. Three-dimensional reconstruction of the superficial multicentric basal cell carcinoma using serial sections and a computer. Am J Dermatopathol 1987; 9: 198-203.
27. Gollnick H, Barona CG, Frank RG, et al,. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15: 374-81.
28. Gollnick H, Barona CG, Frank RG, et al,. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008; 18: 677-82.
29. Li Q, Gao T, Jiao B, et al,. Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types IV/V treated with methyl aminolaevulinate photodynamic therapy. Photomed Laser Surg 2011; 29: 501-7.
30. Christensen E, Mork C, Skogvoll E,. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br J Dermatol 2012; 166: 1342-8.
31. Soler AM, Warloe T, Berner A, Giercksky KE,. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145: 467-71.
32. Fantini F, Greco A, Del Giovane C, et al,. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25: 896-901.
33. Morton CA, MacKie RM, Whitehurst C, et al,. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134: 248-9.
34. Kaur P, Mulvaney M, Carlson JA,. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 2006; 28: 293-307.
35. Urosevic M, Maier T, Benninghoff B, et al,. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325-32.
36. Vidal D, Matias-Guiu X, Alomar A,. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004; 29: 518-25.
37. Betti R, Inselvini E, Carducci M, Crosti C,. Age and site prevalence of histologic subtypes of basal cell carcinomas. Int J Dermatol 1995; 34: 174-6.
38. Raasch BA, Buettner PG, Garbe C,. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol 2006; 155: 401-7.
39. Caresana G, Giardini R,. Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol 2010; 24: 1395-9.
40. Haws AL, Rojano R, Tahan SR, Phung TL,. Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol 2012; 66: 106-11.